Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC S23 at-home 30-minute cancer screening for prostate, bladder, and ovarian cancers; $846K Mayo Clinic/TQ Ventures/YC-backed with synthetic biology + computer vision from Oxford Rhodes Scholar founders competing with GRAIL for accessible early...
Cleancard is a United States-based at-home cancer screening company — backed by Y Combinator (S23) with $846,000 in total funding from Mayo Clinic Platform, TQ Ventures, Urban Innovation Fund, Y Combinator, and the Creative Destruction Lab — developing a 30-minute at-home diagnostic platform that combines synthetic biology, machine learning, and computer vision to detect multiple cancer biomarkers from a single patient sample for prostate, bladder, and ovarian cancers. Founded by Luca Springer and Thomas Carroll (both Rhodes Scholars from Oxford), Cleancard targets the massive unmet need for accessible, affordable cancer screening outside of clinical settings — the 30-minute result time and home-based format enabling screening at the frequency and convenience required for early cancer detection programs.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.